Navigation Links
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Date:6/10/2011

not an ultrasonic nebulizer technology, and it is not a general purpose electronic aerosol generator nebulizer technology.  Combined with its quiet mode of operation, small size, light weight, and battery use, eFlow Technology reduces the burden of taking daily, inhaled treatments.  PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together.  Online at www.paripharma.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial positions, results of operations, the results of clinical trials and clinical data described herein, the development of our products, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of FDA and other regulatory approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, our future clinical trials may not support the data described in this release, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks an
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
2. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
6. PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
7. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
8. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
9. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
10. Baxa Corporation Demonstrates End-to-End Environmental Stewardship
11. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  As the building ... a company access to diverse skill sets and ... round-the clock business hours for efficiency. However, effectively ... According to recent research, more ... as seeing a project not move forward due ...
(Date:10/22/2014)... Oct. 22, 2014  Cephasonics, a technology-innovation leader with ... the cQUB™-1 (cQuest Ultrasound Box™-1), the first product in ... and manufactured by Cephasonics for purchase by companies to ... Cephasonics will be showcasing the cQUB-1 for the first ... in Chongqing, China from October ...
(Date:10/22/2014)...  Quest Diagnostics (NYSE: DGX ), the ... that its Board of Directors has elected Jeffrey M. ... 1, 2014. Including Dr. Leiden, the Board has 11 ... and CEO of Vertex Pharmaceuticals.   Dr. Leiden has ... in the pharmaceutical and biotechnology industries as well as ...
Breaking Medicine Technology:Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3
... June 17 Medical Simulation Corporation (MSC) proudly announces ... New York ,s largest health system and recipient of the ... The agreement includes the sale of MSC,s endovascular simulation system, ... services to advance North Shore,s education and patient safety goals ...
... ePharmaSolutions, a leading provider of clinical research technologies and ... Visit Report) application with new features to support online and offline ... with leading CTMS systems. , ... "Our latest release provides study monitors with the option ...
Cached Medicine Technology:Medical Simulation Corporation Signs Agreement With North Shore-LIJ Health System 2Medical Simulation Corporation Signs Agreement With North Shore-LIJ Health System 3ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities 2
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... getting the right amount of sleep might raise your ... Those who sleep less or more than the recommended ... prone to developing the chronic condition, which causes inflammation ... that duration and quality of sleep are key factors ... "Both short and long durations of sleep have ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... an incidence rate between 0 and 2.6% (average 0.3%) in ... generally well tolerated by patients, causing a delay in medical ... pediatrician faced with diagnosis and treatment of tinea of the ... tinea of the nails was observed in the Hospital del ...
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... Treatment ... Worldwide, LOS ANGELES, Nov. ... develop an AIDS vaccine have,announced that their efforts have stumbled or, in ... was halted last week,when its vaccine was suspected of actually making some ...
... Patients Ages 10 to 17 ... ... ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE:,BMY) announced today that ... a Priority Review to the supplemental New,Drug Application (sNDA) of the atypical ...
... care fraud,becoming more organized, sophisticated, and prevalent, ... Investigative Units,(SIUs), state and federal agencies, and ... Health Care Anti-Fraud Association (NHCAA),s Annual,Training Conference, ... learn,more about new fraud schemes and explore ...
... against prescribing drug to patients who are already depressed ... take the weight-loss drug rimonabant may face heightened risks ... The finding follows a recommendation by a U.S. Food ... not approve the diet drug because of continuing concerns ...
Cached Medicine News:Health News:Tinea of the nails underdiagnosed in children 2Health News:Low standards of child well-being linked to greater income inequality 2Health News:AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 2Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 3Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 2Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 3
... Upper extremity fixator has been designed to ... by allowing independent movement of its clamp ... goals has been to reduce complexity of ... ease of use. The Hoffmann® II Compact™ ...
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
... components for individual indications. XCaliber covers a ... an innovative composite plastic material, XCaliber is ... This means it's easier to handle, easier ... patient. ,Comes pre-assembled, packaged sterile, and ready ...
Medicine Products: